


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Renji Medical Group Ltd
中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND RESUMPTION OF TRADING

This announcement is made at the request of the Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The board (the “Board”) of directors (the “Directors”) of China Renji Medical Group Limited (“Company”, together with its subsidiaries, the “Group”) noted the increases in the price and trading volume of the shares of the Company today. The Board wishes to inform shareholders of the Company and potential investors that the Company is in negotiation for a potential disposal of certain interest in a subsidiary of the Group and is in the course of negotiation with an independent third party on a potential acquisition of a company engaged in the healthcare and fitness business in the People’s Republic of China, both of which may constitute major transactions (the “Possible Transactions”) of the Company when materialized.

It is the Board’s understanding that no agreements in relation to the Possible Transactions have been entered into by the parties concerned as at the date of this announcement. As such, the contemplated Possible Transactions may or may not proceed and further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

As the Possible Transactions may or may not proceed, shareholders of the Company and public investors are advised to exercise caution in dealing with the shares and securities of the Company.

Having made such enquiry with respect of the Company as is reasonable in the circumstances, the Board confirms that save for the aforesaid, it is not aware of any reasons for these price and trading volume movement or of any information which must be announced to avoid a false market in the Company’s shares or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

At the request of the Company, trading in the shares of the Company on the Stock Exchange had been halted with effect from 11:24 a.m. on 8 August 2014 pending the release of this announcement. Application has been made by the Company for the resumption of trading in the shares of the Company with effect from 9:00 a.m. on 11 August 2014.

This announcement is made by the order of the Board. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By Order of the Board of
China Renji Medical Group Limited
Tang Chi Chiu
Chairman

Hong Kong, 8 August 2014

As at the date of this announcement, the board of the Company comprises three executive directors, namely Mr. Tang Chi Chiu, Mr. Chan Ka Chung and Mr. Wang Jianguo, and three independent non-executive directors, namely Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen and Ms. Wu Yan.